GHRP-6 vs GHRP-2 vs Ipamorelin: GHS-R1a Selectivity

TL;DR: GHRP-6, GHRP-2, and ipamorelin are all synthetic GHS-R1a agonists, they stimulate pulsatile growth hormone release by binding the same G protein-coupled receptor first cloned by Howard et al. in 1996. The three compounds differ substantially in selectivity: GHRP-6 produces documented orexigenic effects and significant ACTH/cortisol elevation in human studies; GHRP-2 is more potent for GH release but similarly non-selective, also elevating ACTH, cortisol, and prolactin; ipamorelin is documented as the first GHS-R1a agonist with GH-release selectivity comparable to GHRH, without significant ACTH or cortisol response at GH-releasing doses in preclinical swine models. None of the three are FDA approved, and all are prohibited by WADA under Section S2.

Research-Use Disclaimer: This article is for educational and research reference purposes only. GHRP-6, GHRP-2, and ipamorelin are research compounds, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research or limited human pharmacology studies. For adults 21+ with a research interest only.

What Is the Shared GHS-R1a Mechanism?

Growth hormone-releasing peptides (GHRPs) belong to the broader growth hormone secretagogue (GHS) class, compounds that stimulate GH release through a receptor pathway distinct from the classical GHRH receptor. The receptor target shared by GHRP-6, GHRP-2, and ipamorelin is designated GHS-R1a (growth hormone secretagogue receptor type 1a).

GHS-R1a was first cloned and characterized in a landmark 1996 study by Howard et al. published in Science. According to PubMed, the study identified GHS-R1a as a Gq/11-coupled G protein-coupled receptor (GPCR) expressed in the pituitary gland and the arcuate/ventromedial/infundibular regions of the hypothalamus in both swine and humans. Howard et al. demonstrated that GHS-R1a defines a distinct neuroendocrine pathway for the control of pulsatile GH release and that the GH secretagogues appeared to mimic an undiscovered endogenous hormone, a prediction confirmed four years later when ghrelin was identified as the receptor’s natural ligand.

When GHS-R1a is activated by any of these three GHRPs, the downstream result is episodic, pulsatile GH secretion from anterior pituitary somatotroph cells. This shared mechanism is why all three compounds are studied in the same GH-axis research context. The divergence lies not in the receptor activated, but in which other receptors and hormone axes are engaged simultaneously, and to what degree.

Three-Way Comparison Matrix

The table below summarizes the key pharmacological distinctions across GHRP-6, GHRP-2, and ipamorelin as documented in the peer-reviewed literature. See the individual compound sections below for citations and detail on each dimension.

GHRP-6: Documented Pharmacology and ACTH/Cortisol Profile

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It is one of the earliest and most studied members of the GHRP class, and much of the foundational research establishing the ACTH/cortisol effect of GHRPs was conducted using GHRP-6 as the reference compound.

According to PubMed, a 1995 randomized controlled trial by Frieboes et al., published in Neuroendocrinology, administered repetitive intravenous boluses of GHRP-6 to normal male subjects during the nocturnal period. The study found that GHRP-6 significantly elevated GH concentrations, but also raised ACTH and cortisol levels significantly compared to placebo, with nocturnal cortisol more than doubling in the GHRP-6 condition (56.0 ± 31.0 ng/mL vs. 25.2 ± 9.0 ng/mL, P < 0.02). This was a critical early demonstration that GHRP-6 engages the hypothalamic-pituitary-adrenocortical (HPA) axis in humans, an effect not observed with GHRH, which in fact blunts cortisol. The study described GHRP-6’s action on the HPA axis as opposite to that of GHRH.

A follow-up study by Frieboes et al. (1999), published in the Journal of Neuroendocrinology, explored different routes of GHRP-6 administration and found that intranasal GHRP-6 prompted significant GH increase and a trend toward elevated ACTH, while oral administration produced no significant GH, ACTH, or cortisol changes, demonstrating that the HPA activation is present at pharmacologically active doses and route-dependent.

GHRP-6’s orexigenic properties have been documented in the preclinical literature as a feature of GHS-R1a activation more broadly. The receptor is expressed in hypothalamic regions associated with appetite regulation, and GHRP-6 specifically has been associated with increased food intake in animal models via NPY/AgRP pathway engagement, a distinguishing feature not prominently documented for ipamorelin. This orexigenic effect is mechanistically connected to the same GHS-R1a receptor that mediates GH release, not a separate pharmacological target.

In a 2010 randomized controlled trial by de Sá et al., published in Metabolism, GHRP-6 and ghrelin were both administered intravenously to patients with type 1 diabetes and healthy controls. The study found that ghrelin-induced GH release was higher than that after GHRP-6 in both groups, and that ACTH and cortisol release after ghrelin and GHRP-6 were similar, with neither the GH nor the ACTH/cortisol responses significantly different between T1DM patients and controls. This study established that GHRP-6’s HPA axis engagement is a consistent pharmacological property not altered by diabetic metabolic context.

GHRP-2: High Potency, Non-Selective Profile

GHRP-2 (also called KP-102 or pralmorelin; sequence D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2) is a second-generation synthetic GHRP with substantially higher GH-releasing potency than GHRP-6, while retaining a similarly non-selective side-effect profile. It was among the most extensively studied GHRPs in human clinical pharmacology and remains in use as a diagnostic GH-stimulation tool in Japan under the name pralmorelin.

The potency advantage of GHRP-2 over GHRP-6 was quantified in the Raun et al. (1998) swine study: GHRP-2 demonstrated an in vivo GH-releasing ED50 of approximately 0.6 nmol/kg, roughly 6-fold more potent than GHRP-6 (ED50 ~3.9 nmol/kg) at equivalent maximum GH output. In vitro pituitary cell assays in the same study showed a similar potency advantage for GHRP-2.

However, GHRP-2’s non-selectivity is documented in human studies. According to PubMed, a 1997 comparative study by Arvat et al., published in Peptides, administered GHRP-2 and hexarelin to normal young and elderly adults and measured GH, prolactin, ACTH, and cortisol responses in comparison to GHRH, TRH, and human CRH. The study found that both GHRP-2 and hexarelin induced significant ACTH and cortisol responses with a magnitude comparable to that of human CRH, alongside their GH-releasing effects, and also elevated prolactin, though at lower levels than TRH. The authors concluded that GHRP-2 is “not fully specific” as it induces similar increases in prolactin, ACTH, and cortisol at doses required for GH release in humans.

A separate pharmacological characterization study of KP-102 (GHRP-2) by Doi et al. (2004), published in Arzneimittelforschung, used in vivo and in vitro models across rats and dogs. The study confirmed that KP-102 stimulated ACTH and corticosterone secretion in conscious rats alongside GH, but did not significantly affect prolactin, and demonstrated that its GH-releasing activity was less sensitive to somatostatin suppression than GHRH, operating partly through hypothalamic and partly through direct pituitary mechanisms. The study further documented growth-accelerating effects over three weeks in rats, consistent with the sustained GH-stimulating activity of GHRP-2.

Ipamorelin: Selectivity as a Pharmacological Distinction

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide developed at Novo Nordisk and first described in the literature in 1998. It differs structurally from GHRP-6 and GHRP-2 in lacking the central Ala-Trp dipeptide sequence found in GHRP-1 from which both older compounds are derived. This structural difference is associated with its distinct selectivity profile at GHS-R1a.

The foundational selectivity characterization was performed in the Raun et al. (1998) study in the European Journal of Endocrinology. According to PubMed, this study systematically compared ipamorelin, GHRP-6, and GHRP-2 across GH, FSH, LH, PRL, TSH, ACTH, and cortisol responses in swine. The critical finding: ipamorelin did not release ACTH or cortisol at levels significantly different from those observed following GHRH stimulation alone, even at doses more than 200-fold higher than the GH-releasing ED50, while both GHRP-6 and GHRP-2 produced significant ACTH and cortisol elevations at standard GH-releasing doses. FSH, LH, prolactin, and TSH were unaffected by all three GHSs. The authors described ipamorelin as “the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH.”

This selectivity profile distinguishes ipamorelin as a pharmacological research tool for isolating GHS-R1a-mediated GH effects from the HPA-axis co-stimulation seen with less selective GHRPs. It is important to note this finding originated in a swine model and has not been replicated in large, controlled human efficacy trials. The existing human pharmacokinetic data (Gobburu et al., 1999) documented ipamorelin’s PK parameters and GH-releasing profile in healthy male volunteers but did not measure ACTH or cortisol endpoints. For the full ipamorelin compound profile, see the dedicated post: What Is Ipamorelin? Mechanism and Evidence.

How Does Selectivity Differ? The Mechanistic Explanation

The selectivity differences among these three compounds reflect the structural pharmacology of GHS-R1a activation and the divergent downstream signaling consequences of different ligand-receptor interaction geometries, a concept sometimes called “biased agonism.”

GHS-R1a is a Gq/11-coupled GPCR. Its activation by ghrelin, GHRP-6, or GHRP-2 engages not only pituitary somatotrophs but also hypothalamic neurons that regulate CRH secretion, the upstream driver of the HPA axis. GHRP-6 and GHRP-2 appear to activate both somatotroph GHS-R1a (GH pulse) and CRH-neuronal GHS-R1a (ACTH/cortisol) with similar efficacy. Ipamorelin’s structural modifications, specifically the Aib N-terminal residue and lack of the Ala-Trp dipeptide, appear to confer a binding geometry that produces equivalent somatotroph activation with substantially reduced HPA-axis co-stimulation. The precise molecular mechanism underlying this selectivity difference remains an active area of investigation.

GHRP-6’s additional orexigenic effect is mechanistically linked to GHS-R1a expression in the hypothalamic arcuate nucleus, where activation interacts with NPY/AgRP circuits. This is a shared property of GHS-R1a agonism broadly, but appears more pronounced with GHRP-6 than with more selective compounds, consistent with GHRP-6’s less discriminating receptor engagement profile.

For a broader overview of the GH axis and all GHS compounds covered in the Legendary Labz guide, see the GH Axis & Secretagogues cluster overview and the mechanism comparisons pillar.

Evidence by Tier: What the Research Base Actually Shows

All three compounds sit at Tier 2 in the Legendary Labz evidence framework, but the nature and depth of their respective evidence bases differ meaningfully. For methodology, see How to Read an Evidence Tier.

Critical limitation applicable to all three compounds: preclinical pharmacology findings, including the pivotal selectivity data for ipamorelin and the ACTH/cortisol effect data for GHRP-6 and GHRP-2, were obtained in animal models (predominantly rats and swine) or in short-duration human pharmacology studies. These findings do not establish efficacy or safety for any therapeutic endpoint in humans. The degree to which preclinical selectivity profiles translate to human physiology remains scientifically unestablished. No large, placebo-controlled, long-term human efficacy RCTs have been published for any of these three compounds as of 2026.

Regulatory and Anti-Doping Status

FDA (United States)

None of the three compounds, GHRP-6, GHRP-2, or ipamorelin, are approved by the U.S. Food and Drug Administration as drugs, biologics, or dietary supplement ingredients. None have authorized human dosing protocols or approved indications in the United States. Pralmorelin (GHRP-2) has regulatory approval in Japan solely as a diagnostic agent for GH stimulation testing, not as a therapeutic. Researchers should consult current FDA guidance directly regarding the classification and regulatory status of each compound.

WADA (World Anti-Doping Agency)

All three compounds are prohibited under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics on the WADA Prohibited List. Section S2 covers all GH-releasing peptides and mimetics. The prohibition applies both in-competition and out-of-competition for athletes subject to WADA rules. WADA has developed detection methodology for GHRPs in biological samples; researchers designing doping control studies should consult the current WADA Technical Document.

Frequently Asked Questions

What is the main difference between GHRP-6, GHRP-2, and ipamorelin?

All three are GHS-R1a agonists that stimulate pulsatile GH release, but they differ substantially in selectivity. In the landmark 1998 Raun et al. study in the European Journal of Endocrinology, ipamorelin did not significantly elevate ACTH or cortisol in swine even at doses more than 200-fold above its GH-releasing ED50, while both GHRP-6 and GHRP-2 produced significant ACTH and cortisol responses at standard GH-releasing doses. GHRP-6 additionally demonstrates orexigenic effects not prominently observed with ipamorelin. This is a preclinical selectivity distinction and has not been confirmed in large-scale human trials.

Does GHRP-6 raise cortisol?

Yes, based on published human data. The 1995 Frieboes et al. randomized controlled trial (PMID 7617137, Neuroendocrinology) documented significant nocturnal cortisol elevation after intravenous GHRP-6 in healthy men, more than double placebo levels. This HPA-axis engagement is a consistent finding across multiple GHRP-6 studies and distinguishes GHRP-6 from both GHRH and ipamorelin in the published pharmacology literature.

Is ipamorelin more selective than GHRP-2?

Based on current evidence, yes. Raun et al. (1998) showed no significant ACTH or cortisol elevation with ipamorelin at doses 200-fold above the GH ED50 in swine. Arvat et al. (1997) documented that GHRP-2 produces ACTH and cortisol responses in humans comparable to human CRH in magnitude. Ipamorelin’s selectivity advantage is a preclinical finding; it has not been formally compared to GHRP-2 in a controlled human pharmacology trial measuring both GH and HPA-axis endpoints.

Are GHRP-6, GHRP-2, and ipamorelin prohibited by WADA?

Yes. All three are prohibited under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics on the WADA Prohibited List, both in-competition and out-of-competition, for all athletes subject to WADA anti-doping rules.

For educational and research reference purposes only. Not medical advice. Not for human use.